Marshall Urist Biography and Net Worth

EVP of Royalty Pharma

Dr. Urist Joined Royalty Pharma in 2013. Previously, Dr. Urist was an executive director and the senior biotechnology analyst at Morgan Stanley. Dr. Urist has a BA, Phi Beta Kappa, from Johns Hopkins University, a PhD from Columbia University, and an MD from Columbia University.

What is Marshall Urist's net worth?: The estimated net worth of Marshall Urist is at least $1.00 million as of December 1st, 2025. Dr. Urist owns 25,640 shares of Royalty Pharma stock worth more than $1,003,806 as of December 4th. This net worth approximation does not reflect any other assets that Dr. Urist may own. Additionally, Dr. Urist receives a salary of $4,560,000.00 as EVP at Royalty Pharma. Learn More about Marshall Urist's net worth.
How old is Marshall Urist?: Dr. Urist is currently 48 years old. There are 5 older executives and no younger executives at Royalty Pharma. Learn More on Marshall Urist's age.
What is Marshall Urist's salary?: As the EVP of Royalty Pharma PLC, Dr. Urist earns $4,560,000.00 per year. Learn More on Marshall Urist's salary.
How do I contact Marshall Urist?: The corporate mailing address for Dr. Urist and other Royalty Pharma executives is 110 E 59th Street, New York NY, 10022. Royalty Pharma can also be reached via phone at 212-883-0200 and via email at [email protected]. Learn More on Marshall Urist's contact information.
Has Marshall Urist been buying or selling shares of Royalty Pharma?: During the last quarter, Marshall Urist has sold $1,659,542.49 in shares of Royalty Pharma stock. Most recently, Marshall Urist sold 18,242 shares of the business's stock in a transaction on Monday, December 1st. The shares were sold at an average price of $39.90, for a transaction totalling $727,855.80. Following the completion of the sale, the executive vice president now directly owns 25,640 shares of the company's stock, valued at $1,023,036. Learn More on Marshall Urist's trading history.
Who are Royalty Pharma's active insiders?: Royalty Pharma's insider roster includes Terrance Coyne (CFO), Henry Fernandez (Director), William Ford (Director), Mario Giuliani (Director), Pablo Legorreta (Founder & Chief Executive Officer and Chairman), George Lloyd (EVP), James Reddoch (EVP), Rory Riggs (Director), Sanjay Singh (CRO), and Marshall Urist (EVP). Learn More on Royalty Pharma's active insiders.
Are insiders buying or selling shares of Royalty Pharma?: In the last twelve months, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 455,353 shares worth more than $17,778,484.17. The most recent insider tranaction occured on December, 1st when CFO Terrance P Coyne sold 69,582 shares worth more than $2,774,234.34. Insiders at Royalty Pharma own 18.9% of the company. Learn More about insider trades at Royalty Pharma.
Information on this page was last updated on 12/1/2025.

Marshall Urist Insider Trading History at Royalty Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/1/2025	Sell	18,242	$39.90	$727,855.80	25,640
12/1/2025	Sell	23,333	$39.93	$931,686.69	183,334
2/22/2023	Sell	23,333	$37.30	$870,320.90	46,667
6/24/2022	Sell	23,333	$43.19	$1,007,752.27	23,334
5/16/2022	Sell	23,333	$39.85	$929,820.05	46,667
6/7/2021	Sell	16,568	$47.02	$779,027.36	16,568
6/4/2021	Sell	16,566	$45.13	$747,623.58	16,568
6/2/2021	Sell	14,566	$41.52	$604,780.32

Marshall Urist Buying and Selling Activity at Royalty Pharma

Royalty Pharma Company Overview

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Today's Range

Now: $39.15

$38.98

$39.64

50 Day Range

MA: $37.77

$35.04

$40.78

2 Week Range

Now: $39.15

$24.05

$41.24

Volume

4,401,552 shs

Average Volume

4,120,751 shs

Market Capitalization

$22.60 billion

P/E Ratio

29.66

Dividend Yield

2.22%

Beta

0.47

Marshall Urist Biography and Net Worth

What is Marshall Urist's net worth?

How old is Marshall Urist?

What is Marshall Urist's salary?

How do I contact Marshall Urist?

Has Marshall Urist been buying or selling shares of Royalty Pharma?

Who are Royalty Pharma's active insiders?

Are insiders buying or selling shares of Royalty Pharma?